[{"address1": "3963 Maple Avenue", "address2": "Suite 350", "city": "Dallas", "state": "TX", "zip": "75219", "country": "United States", "phone": "972 499 3350", "website": "https://instilbio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.", "fullTimeEmployees": 49, "companyOfficers": [{"maxAge": 1, "name": "Mr. Bronson  Crouch", "age": 50, "title": "Chairman & CEO", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 1140189, "exercisedValue": 0, "unexercisedValue": 35349}, {"maxAge": 1, "name": "Dr. Sandeep  Laumas M.D.", "age": 54, "title": "CFO & Chief Business Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 741521, "exercisedValue": 0, "unexercisedValue": 61910}, {"maxAge": 1, "name": "Dr. Mark E. Dudley Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1730073600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 34.41, "open": 33.75, "dayLow": 33.75, "dayHigh": 34.84, "regularMarketPreviousClose": 34.41, "regularMarketOpen": 33.75, "regularMarketDayLow": 33.75, "regularMarketDayHigh": 34.84, "beta": 1.629, "forwardPE": -3.4211574, "volume": 107570, "regularMarketVolume": 107570, "averageVolume": 272468, "averageVolume10days": 138800, "averageDailyVolume10Day": 138800, "bid": 33.98, "ask": 34.68, "bidSize": 100, "askSize": 100, "marketCap": 222954032, "fiftyTwoWeekLow": 6.08, "fiftyTwoWeekHigh": 92.0, "fiftyDayAverage": 39.5143, "twoHundredDayAverage": 18.309, "currency": "USD", "enterpriseValue": 159796144, "floatShares": 2312531, "sharesOutstanding": 6503910, "sharesShort": 334867, "sharesShortPriorMonth": 259469, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0515, "heldPercentInsiders": 0.12863, "heldPercentInstitutions": 0.75841004, "shortRatio": 1.05, "shortPercentOfFloat": 0.08930001, "bookValue": 29.985, "priceToBook": 1.1432382, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -119576000, "trailingEps": -18.39, "forwardEps": -10.02, "enterpriseToEbitda": -2.42, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "TIL", "underlyingSymbol": "TIL", "shortName": "Instil Bio, Inc.", "longName": "Instil Bio, Inc.", "firstTradeDateEpochUtc": 1616160600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f6e98ce3-ca96-34e6-a1c6-796bed2d60df", "gmtOffSetMilliseconds": -14400000, "currentPrice": 34.28, "targetHighPrice": 180.0, "targetLowPrice": 11.0, "targetMeanPrice": 103.67, "targetMedianPrice": 120.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 148772992, "totalCashPerShare": 22.874, "ebitda": -66022000, "totalDebt": 85615000, "quickRatio": 14.459, "currentRatio": 15.057, "debtToEquity": 43.901, "returnOnAssets": -0.1245, "returnOnEquity": -0.48654, "freeCashflow": -27199750, "operatingCashflow": -52811000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-31"}]